Cellectis SA (CLLS) has released an update.
Cellectis SA, a clinical-stage biotech company, has just appointed Dr. Adrian Kilcoyne as the new Chief Medical Officer, strengthening its leadership in pioneering gene-editing and cell therapy technologies. Dr. Kilcoyne brings extensive experience from his previous roles at Celularity and Humanigen, aiming to advance Cellectis’ innovative CAR T-cell therapies. The company continues its mission to meet significant unmet medical needs with its promising product pipeline and experienced team.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
